Abstract: TH-PO693
Suppression of Thyroid Profile During Roxadustat Treatment in CKD Patients
Session Information
- Anemia and Iron Metabolism
November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Anemia and Iron Metabolism
- 200 Anemia and Iron Metabolism
Authors
- Cheng, Yuan, 1Department of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, P.R. China, Shenzhen, China
- Xiang, Qiong, 1Department of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, P.R. China, Shenzhen, China
- Cao, Tao, 1Department of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, P.R. China, Shenzhen, China
- Tang, Fei, 1Department of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, P.R. China, Shenzhen, China
- Wan, Qijun, 1Department of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, P.R. China, Shenzhen, China
Background
Roxadustat has been used for renal anemia. To date, roxadustat induced suppression of thyrotropin secretion have been only described in two cases reports, but more data from a larger cohor are needed.
Methods
A total of 151 patients with renal anemia were collected in this retrospective cohort study. Changes in thyroid hormone and TSH were evaluated before and during the use of roxadustat or erythropoietin.
Results
FT3, FT4, T3, T4 and TSH level were lower during the use of roxadustat compared to baseline compared to erythropoietin group. 48.68% of patients had TSH levels dropped by more than 50%. By multivariate analysis, treatment of roxadustat was independently associated with the lower of TSH level by 41.30% (P<0.001).
Conclusion
This corhort study first finds that the suppression of thyroid profile is commonly related in CKD patients used roxadustat.
Multivariate regression
| Unadjusted | Model 1 | Model 2 | ||||
| β (95% CI) | P | β (95% CI) | P | β (95% CI) | P | |
| Erythropoietin | reference | reference | reference | |||
| Roxadustat | ||||||
| Percent change of T3, % | -22.62 (-35.58, -9.66) | 0.001 | -21.85 (-35.48, -8.22) | 0.003 | -14.92 (-31.61, -1.77) | 0.086 |
| Percent change of T4, % | -30.94 (-43.77, -18.12) | <0.001 | -27.05 (-39.87, -14.22) | <0.001 | -21.87 (-38.15, -5.59) | <0.001 |
| Percent change of FT3, % | -19.19 (-28.81, -9.58) | <0.001 | -20.13 (-29.85, -10.40) | <0.001 | -18.75 (-30.77, -6.73) | <0.001 |
| Percent change of FT4, % | -9.48 (-14.24, -4.73) | <0.001 | -9.93 (-14.74, -5.13) | <0.001 | -9.32 (-15.26, -3.39) | <0.001 |
| Percent change of TSH, % | -35.77 (-50.95, -20.58) | <0.001 | -34.32 (-49.69, -18.95) | <0.001 | -41.30 (-59.76, -22.83) | <0.001 |
Model 1 is adjusted for sex, age, BMI, DM and hypertension. Model 2 is adjusted for variables in Model 1 and, CRP, serum albumin, uric acid, total cholesterol and transferrin saturation.
TSH change
TSH decline >50%
Funding
- Government Support – Non-U.S.